| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/18/2001 | EP1091751A1 Trimeric antigenic o-linked glycopeptide conjugates, methods of preparation and uses thereof |
| 04/18/2001 | EP1091750A1 Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
| 04/18/2001 | EP1091740A1 Semi-solid aqueous preparations for oral applications of toltrazuril sulphone |
| 04/18/2001 | EP1091732A1 Effervescent drug delivery system for oral administration |
| 04/18/2001 | EP0796240B1 Lipopolyamines as transfection agents and pharmaceutical uses thereof |
| 04/18/2001 | EP0766566B1 A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
| 04/18/2001 | EP0683804B1 Methods of polymer impregnation |
| 04/18/2001 | EP0576478B2 Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a |
| 04/18/2001 | EP0572429B1 Sulfonyl urea derivates, method for preparing them and use thereof |
| 04/18/2001 | CN1291897A Inorganic nitrite and organic acid in combination as topical antiviral composition |
| 04/18/2001 | CN1291886A Formulations |
| 04/18/2001 | CN1291868A Sweetening agent |
| 04/18/2001 | CN1291474A Taxusol-lipid composition and its preparing process |
| 04/18/2001 | CN1064531C Process for preparation of injectable ready-to use solution containing antitumor anthracycline glycoside |
| 04/17/2001 | US6218516 Monoclonal antibody that binds to a animal growth regulator domain; for treatment of metastasis |
| 04/17/2001 | US6218440 Hydrophilic polymeric material and method of preparation |
| 04/17/2001 | US6218438 N-aroyl hydrazone poly(oxyethylene)-poly(oxypropylene) nonionic block copolymer; hiv |
| 04/17/2001 | US6218399 Modifying the 20 position of camptothecin to form a compound which is low toxicity used in cancer therapy |
| 04/17/2001 | US6218375 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin and method |
| 04/17/2001 | US6218374 Pharmaceutical formulation |
| 04/17/2001 | US6218373 Formulations containing hyaluronic acid |
| 04/17/2001 | US6218370 Useful for cell transfection |
| 04/17/2001 | US6218369 Administering flavanolignane selected from silymarin, silybin, silidianin, silicristin, dehydrosilybin, phospholipid complex of one of these flavanolignanes, and mixtures, in combination with antitumor agent |
| 04/17/2001 | US6218148 DNS encoding stem cell factor |
| 04/17/2001 | US6217912 Polyester analogue of poly-L-lysine as a soluble, biodegradable gene delivery carrier |
| 04/17/2001 | US6217909 Pharmaceutical excipient having improved compressibility |
| 04/17/2001 | US6217908 Administering to mucous membranes |
| 04/17/2001 | US6217907 Directly compressible high load acetaminophen formulations |
| 04/17/2001 | US6217904 Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant |
| 04/17/2001 | US6217897 Anhydrous spreadable mucoadhesive |
| 04/17/2001 | US6217893 Sustained-release compositions and method for preparing same |
| 04/17/2001 | US6217886 Materials and methods for making improved micelle compositions |
| 04/17/2001 | US6217874 Glyceride mixture |
| 04/17/2001 | US6217873 Polyoxime compounds and their preparation |
| 04/17/2001 | US6217869 Administering antibody, antigen, ligand complex |
| 04/17/2001 | US6217867 Administering radiation; monoclonal antibodies |
| 04/17/2001 | US6217858 Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
| 04/17/2001 | US6217845 Protein labelling |
| 04/17/2001 | CA2163107C Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates |
| 04/17/2001 | CA2055493C Antineoplastic solution and method for treating neoplasms |
| 04/17/2001 | CA2052323C Oligosaccharide conjugate vaccines |
| 04/14/2001 | CA2323717A1 Process for limiting penetration of skin and/or keratinous tissue by an active pharmaceutical and/or cosmetic agent |
| 04/12/2001 | WO2001025446A1 Dna encoding prost 07 polypeptide |
| 04/12/2001 | WO2001025414A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 04/12/2001 | WO2001025410A2 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 04/12/2001 | WO2001025393A1 Elastic article |
| 04/12/2001 | WO2001025322A1 Water unstable foam |
| 04/12/2001 | WO2001025295A1 Crosslinked copolymers based on non-crosslinked polycarboxylic copolymers |
| 04/12/2001 | WO2001025248A2 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | WO2001025209A1 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
| 04/12/2001 | WO2001025208A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 04/12/2001 | WO2001024842A2 Hybrid matrices and hybrid matrix mixtures |
| 04/12/2001 | WO2001024839A1 Silver-containing compositions, devices and methods for making |
| 04/12/2001 | WO2001024831A2 Polymer stabilized neuropeptides |
| 04/12/2001 | WO2001024829A2 Binding agents |
| 04/12/2001 | WO2001024817A2 Pharmaceutical compositions of fibrinolytic agent |
| 04/12/2001 | WO2001024814A1 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 04/12/2001 | WO2001024813A1 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| 04/12/2001 | WO2001024812A1 USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| 04/12/2001 | WO2001024807A2 Method for calming human beings using personal care compositions |
| 04/12/2001 | WO2001024804A2 Method for preparing a composition by mother-of-pearl extraction, and use thereof in cosmetics and dermatology |
| 04/12/2001 | WO2001024801A1 Pharmaceutical formulations containing poorly soluble drug substances |
| 04/12/2001 | WO2001024800A1 Erection insufficiency remedies |
| 04/12/2001 | WO2001024799A1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 04/12/2001 | WO2001024795A1 RETARD FORM CONTAINING α-LIPOIC ACID (DERIVATIVES) |
| 04/12/2001 | WO2001024793A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 04/12/2001 | WO2001024788A2 Treating endometriosis or infertility, or improving fertility |
| 04/12/2001 | WO2001024780A2 Soft gel capsule resistant to gastric juices |
| 04/12/2001 | WO2001024779A1 Foam coatings and foam coated compositions |
| 04/12/2001 | WO2001024778A1 Anti-inflammatory pharmaceutical formulations |
| 04/12/2001 | WO2001024777A1 Coated solid dosage forms |
| 04/12/2001 | WO2001024776A1 Biodegradable excipient systems for therapeutically active substances and method for producing the same |
| 04/12/2001 | WO2001024775A1 Gel-forming compositions |
| 04/12/2001 | WO2001024774A1 Ortho ester lipids |
| 04/12/2001 | WO2001024773A1 Liposome-entrapped dna oral vaccines |
| 04/12/2001 | WO2001024765A2 Antigenic modification of polypeptides |
| 04/12/2001 | WO2001024764A2 Cell targeting compositions and methods of using the same |
| 04/12/2001 | WO2001024763A2 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 04/12/2001 | WO2001000230A8 Drug composition containing lecithin-modified superoxide dismutase |
| 04/12/2001 | WO2000004891A3 Anti-ulcer composition |
| 04/12/2001 | WO1999063939A9 Multibinding inhibitors of cyclooxygenase-2 |
| 04/12/2001 | WO1998025575A3 Improved hydrogel composition |
| 04/12/2001 | US20010000230 Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| 04/12/2001 | CA2406882A1 Diagnostic probes and therapeutics targeting upa and upar |
| 04/12/2001 | CA2388864A1 Ortho ester lipids |
| 04/12/2001 | CA2387703A1 Method for calming human beings using personal care compositions |
| 04/12/2001 | CA2387288A1 Anti-inflammatory pharmaceutical formulations |
| 04/12/2001 | CA2386461A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 04/12/2001 | CA2386377A1 Cell targeting compositions and methods of using the same |
| 04/12/2001 | CA2386307A1 Binding agents |
| 04/12/2001 | CA2386277A1 An improved pharmaceutical composition and a process for its preparation |
| 04/12/2001 | CA2386228A1 Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides |
| 04/12/2001 | CA2386024A1 Liposome-entrapped dna oral vaccines |
| 04/12/2001 | CA2385966A1 Pharmaceutical compositions of fibrinolytic agent |
| 04/12/2001 | CA2385853A1 Design of high affinity rnase h recruiting oligonucleotide |
| 04/12/2001 | CA2385696A1 Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| 04/12/2001 | CA2385528A1 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 04/12/2001 | CA2385249A1 Foam coatings and foam coated compositions |
| 04/12/2001 | CA2385213A1 Elastic article |
| 04/12/2001 | CA2385161A1 Water unstable foam |